|1.||Müller, Mathias: 6 articles (11/2015 - 01/2007)|
|2.||Strobl, Birgit: 4 articles (11/2015 - 01/2010)|
|3.||Lassnig, Caroline: 2 articles (11/2015 - 06/2014)|
|4.||Decker, Thomas: 2 articles (11/2015 - 01/2009)|
|5.||Hainzl, Eva: 2 articles (11/2015 - 06/2014)|
|6.||Bradbury, Neil A: 2 articles (06/2015 - 01/2013)|
|7.||Rigler, Doris: 2 articles (07/2014 - 01/2007)|
|8.||Karaghiosoff, Marina: 2 articles (06/2014 - 01/2007)|
|9.||Rülicke, Thomas: 2 articles (06/2014 - 01/2007)|
|10.||Kolbe, Thomas: 2 articles (06/2014 - 01/2007)|
06/01/2014 - "Tyrosine kinase 2 (TYK2) has a pivotal role in immunity to infection and tumor surveillance. "
06/01/2012 - "We describe a Turkish patient with tyrosine kinase 2 deficiency who suffered from disseminated Bacille Calmette-Guerin infection, neurobrucellosis, and cutaneous herpes zoster infection. "
01/01/2011 - "In this study, we showed that infection of airway epithelial cells with hMPV decreased cellular level of Janus tyrosine kinase (Jak1) and tyrosine kinase 2 (Tyk2), due to enhanced proteosomal degradation and reduced gene transcription. "
04/25/2009 - "In this study we show that when type I IFN is added to primary human fibroblasts following MV infection, the tyrosine phosphorylation of the Janus kinase Tyk2 is specifically blocked, thereby preventing the subsequent activation of downstream STAT1 and STAT2. "
02/01/2009 - "Recent studies have demonstrated that hypomorphic mutations in signal transducer and activator of transcription 3 result in the classical multisystem form of HIES, whereas a null mutation in tyrosine kinase 2 causes the autosomal recessive form of HIES that is associated with viral and mycobacterial infections. "
04/01/2008 - "Recent studies have shown that Janus tyrosine kinase 2 (JAK2) V617F mutation is found in nearly all patients with polycythemia vera (PV) and underlie the basis of PV molecular pathogenesis. "
08/01/2006 - "The recent discovery of the new mutation affecting the Janus tyrosine kinase 2 (JAK2V617F), more frequently observed in patients with polycythemia vera, is seen in approximately 35% to 57% of patients with CIMF. "
01/01/2008 - "The JAK family consists of four different JAK kinasesJAK1, JAK2, JAK3, and tyrosine kinase 2. Recent studies have found that JAK2V617F mutation is present in approximately 90-95% of patients with polycythemia vera (PV), and also in approximately half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF). "
12/25/2008 - "We searched for abnormalities of the proapoptotic Bcl-x(L) deamidation pathway in primary cells from patients with chronic myeloid leukemia (CML) or polycythemia vera, myeloproliferative disorders associated with the BCR-ABL fusion kinase and the Janus tyrosine kinase 2 (JAK2) V617F mutation, respectively. "
|3.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
06/01/2007 - "This is a family-based association study to investigate the genetic contribution of tyrosine kinase 2 (TYK2 ) to disease susceptibility in 380 UK systemic lupus erythematosus (SLE) families, consisting of parents and affected offspring. "
06/01/2007 - "We defined a 2.8 kb core association region in TYK2, between these two variants, which narrows down the 5.7 kb gap in the study by Sigurdsson et al. (Sigurdsson S, Nordmark G, Goring HH et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. "
01/01/2009 - "Tyrosine kinase 2 (TYK2) is a type I interferon (IFN) signaling pathway gene and was previously reported to be a risk factor for systemic lupus erythematosus (SLE) in Caucasian populations. "
03/01/2005 - "Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus."
09/01/2012 - "The aim of this study was to determine whether phox homology domain containing serine/threonine kinase (PXK) and tyrosine kinase 2 (TYK2) confer susceptibility to systemic lupus erythematosus (SLE). "
|4.||Job's Syndrome (Hyper-IgE Syndrome)
06/01/2012 - "A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome."
01/01/2011 - "A mutation in the dedicator of the cytokinesis 8 gene has been identified as the cause of many cases with autosomal recessive hyper-IgE syndrome and, in one patient, a mutation in tyrosine kinase 2 gene has been demonstrated. "
07/01/2012 - "Signal transducer and activator of transcription 3 (STAT3) signaling, dedicator of cytokinesis 8 (DOCK8) signaling, and tyrosine kinase 2 (TYK2) signaling alterations have been implicated in 3 forms of hyper-IgE syndrome."
10/01/2009 - "Recent studies have demonstrated that dominant-negative mutations in the signal transducer and activator of transcription 3 (STAT3) gene result in the classical multisystem form of HIES, whereas a null mutation in the tyrosine kinase 2 (TYK2) gene causes an autosomal recessive HIES associated with viral and mycobacterial infections. "
11/15/2015 - "Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis."
08/01/2015 - "To study the preventive effect of sophocarpine (Soc) on dextran sulfate sodium (DSS)-induced colitis in mice, in order to analyze the influence of Soc on toll like receptor 4 (TLR4)/mitogen-activated protein kinases (MAPKs) and janus tyrosine kinase 2 signal transducer and activator of transcription 3 (JAK2/STAT3) signal pathways in mice intestinal tissues. "
|1.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|5.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|6.||Protein Kinases (Protein Kinase)
|7.||alpha- cyano- (3,4- dihydroxy)- N- benzylcinnamide
|9.||Toll-Like Receptor 4
|10.||JNK Mitogen-Activated Protein Kinases